Literature DB >> 23223242

Pathogenic serum amyloid A 1.1 shows a long oligomer-rich fibrillation lag phase contrary to the highly amyloidogenic non-pathogenic SAA2.2.

Saipraveen Srinivasan1, Sanket Patke, Yun Wang, Zhuqiu Ye, Jeffrey Litt, Sunit K Srivastava, Maria M Lopez, Dmitry Kurouski, Igor K Lednev, Ravi S Kane, Wilfredo Colón.   

Abstract

Serum amyloid A (SAA) is best known for being the main component of amyloid in the inflammation-related disease amyloid A (AA) amyloidosis. Despite the high sequence identity among different SAA isoforms, not all SAA proteins are pathogenic. In most mouse strains, the AA deposits mostly consist of SAA1.1. Conversely, the CE/J type mouse expresses a single non-pathogenic SAA2.2 protein that is 94% identical to SAA1.1. Here we show that SAA1.1 and SAA2.2 differ in their quaternary structure, fibrillation kinetics, prefibrillar oligomers, and fibril morphology. At 37 °C and inflammation-related SAA concentrations, SAA1.1 exhibits an oligomer-rich fibrillation lag phase of a few days, whereas SAA2.2 shows virtually no lag phase and forms small fibrils within a few hours. Deep UV resonance Raman, far UV-circular dichroism, atomic force microscopy, and fibrillation cross-seeding experiments suggest that SAA1.1 and SAA2.2 fibrils possess different morphology. Both the long-lived oligomers of pathogenic SAA1.1 and the fleeting prefibrillar oligomers of non-pathogenic SAA2.2, but not their respective amyloid fibrils, permeabilized synthetic bilayer membranes in vitro. This study represents the first comprehensive comparison between the biophysical properties of SAA isoforms with distinct pathogenicities, and the results suggest that structural and kinetic differences in the oligomerization-fibrillation of SAA1.1 and SAA2.2, more than their intrinsic amyloidogenicity, may contribute to their diverse pathogenicity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23223242      PMCID: PMC3554940          DOI: 10.1074/jbc.M112.394155

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

Review 1.  Amyloid precursors and amyloidosis in rheumatoid arthritis.

Authors:  G Cunnane; A S Whitehead
Journal:  Baillieres Best Pract Res Clin Rheumatol       Date:  1999-12       Impact factor: 4.098

2.  Nature of cross-seeding barriers of amyloidogenesis.

Authors:  Dariusz Stępkowski; Juliusz Bieniaś
Journal:  Acta Biochim Pol       Date:  2012-05-11       Impact factor: 2.149

3.  Impact of the antimicrobial peptide Novicidin on membrane structure and integrity.

Authors:  Søren B Nielsen; Daniel E Otzen
Journal:  J Colloid Interface Sci       Date:  2010-01-28       Impact factor: 8.128

4.  Urea-induced denaturation of apolipoprotein serum amyloid A reveals marginal stability of hexamer.

Authors:  Limin Wang; Wilfredo Colón
Journal:  Protein Sci       Date:  2005-06-03       Impact factor: 6.725

5.  Serum amyloid A protein binds to outer membrane protein A of gram-negative bacteria.

Authors:  Ranjeeta Hari-Dass; Chandrabala Shah; David J Meyer; John G Raynes
Journal:  J Biol Chem       Date:  2005-02-10       Impact factor: 5.157

6.  Electrophysiologic properties of channels induced by Abeta25-35 in planar lipid bilayers.

Authors:  Meng-chin Allison Lin; Bruce L Kagan
Journal:  Peptides       Date:  2002-07       Impact factor: 3.750

7.  Recombinant human serum amyloid A (apoSAAp) binds cholesterol and modulates cholesterol flux.

Authors:  J S Liang; J D Sipe
Journal:  J Lipid Res       Date:  1995-01       Impact factor: 5.922

8.  Acceleration of murine AA amyloid deposition by bovine amyloid fibrils and tissue homogenates.

Authors:  Dan Cui; Hiroo Kawano; Yoshinobu Hoshii; Ye Liu; Tokuhiro Ishihara
Journal:  Amyloid       Date:  2008-06       Impact factor: 7.141

Review 9.  Serum amyloid A: an acute-phase protein involved in tumour pathogenesis.

Authors:  E Malle; S Sodin-Semrl; A Kovacevic
Journal:  Cell Mol Life Sci       Date:  2009-01       Impact factor: 9.261

10.  Characterization of the inbred CE/J mouse strain as amyloid resistant.

Authors:  J D Sipe; I Carreras; W A Gonnerman; E S Cathcart; M C de Beer; F C de Beer
Journal:  Am J Pathol       Date:  1993-11       Impact factor: 4.307

View more
  18 in total

1.  Serum amyloid A1 isoforms display different efficacy at Toll-like receptor 2 and formyl peptide receptor 2.

Authors:  Mingjie Chen; Huibing Zhou; Ni Cheng; Feng Qian; Richard D Ye
Journal:  Immunobiology       Date:  2014-08-10       Impact factor: 3.144

2.  Amyloid and inflammation.

Authors:  Peter D Gorevic
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-25       Impact factor: 11.205

3.  Infrared and Raman chemical imaging and spectroscopy at the nanoscale.

Authors:  Dmitry Kurouski; Alexandre Dazzi; Renato Zenobi; Andrea Centrone
Journal:  Chem Soc Rev       Date:  2020-05-19       Impact factor: 54.564

4.  Myeloperoxidase-mediated Methionine Oxidation Promotes an Amyloidogenic Outcome for Apolipoprotein A-I.

Authors:  Gary K L Chan; Andrzej Witkowski; Donald L Gantz; Tianqi O Zhang; Martin T Zanni; Shobini Jayaraman; Giorgio Cavigiolio
Journal:  J Biol Chem       Date:  2015-03-10       Impact factor: 5.157

Review 5.  Amyloid-Forming Properties of Human Apolipoproteins: Sequence Analyses and Structural Insights.

Authors:  Madhurima Das; Olga Gursky
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

6.  Thermal transitions in serum amyloid A in solution and on the lipid: implications for structure and stability of acute-phase HDL.

Authors:  Shobini Jayaraman; Christian Haupt; Olga Gursky
Journal:  J Lipid Res       Date:  2015-05-28       Impact factor: 5.922

7.  High-density lipoprotein inhibits serum amyloid A-mediated reactive oxygen species generation and NLRP3 inflammasome activation.

Authors:  Preetha Shridas; Maria C De Beer; Nancy R Webb
Journal:  J Biol Chem       Date:  2018-07-05       Impact factor: 5.157

Review 8.  Targeting protein aggregation for the treatment of degenerative diseases.

Authors:  Yvonne S Eisele; Cecilia Monteiro; Colleen Fearns; Sandra E Encalada; R Luke Wiseman; Evan T Powers; Jeffery W Kelly
Journal:  Nat Rev Drug Discov       Date:  2015-09-04       Impact factor: 84.694

9.  Divergent effect of glycosaminoglycans on the in vitro aggregation of serum amyloid A.

Authors:  J Javier Aguilera; Fuming Zhang; Julie M Beaudet; Robert J Linhardt; Wilfredo Colón
Journal:  Biochimie       Date:  2014-05-28       Impact factor: 4.079

Review 10.  Serum amyloid A1: Structure, function and gene polymorphism.

Authors:  Lei Sun; Richard D Ye
Journal:  Gene       Date:  2016-03-03       Impact factor: 3.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.